Comparative Pharmacology
Head-to-head clinical analysis: ACCUTANE versus TEGISON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACCUTANE versus TEGISON.
ACCUTANE vs TEGISON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Retinoid that reduces sebum production, normalizes follicular keratinization, and decreases Propionibacterium acnes growth by binding to nuclear retinoic acid receptors, altering gene expression.
Retinoid that binds to nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating gene transcription involved in cell differentiation, proliferation, and apoptosis. It reduces epidermal proliferation and promotes normal keratinization.
Isotretinoin 0.5-1 mg/kg/day orally in 2 divided doses for 15-20 weeks.
Initial dose: 0.5-1 mg/kg/day orally, divided twice daily; maintenance dose: 0.3-0.5 mg/kg/day. Maximum dose: 1.5 mg/kg/day.
None Documented
None Documented
Terminal elimination half-life of isotretinoin is 10-20 hours. The half-life of the major metabolite, 4-oxo-isotretinoin, is 11-50 hours. The long half-life of the metabolite may contribute to sustained clinical effects.
Terminal elimination half-life is approximately 120-168 hours (5-7 days) due to extensive tissue storage; clinical effects persist for weeks after discontinuation.
Renal and biliary: approximately equal amounts of metabolites are excreted in urine and feces. Unchanged drug is not excreted. Major metabolites: 4-oxo-isotretinoin, tretinoin, 4-oxo-tretinoin. Renal excretion of metabolites accounts for ~65-83% of the dose; fecal excretion accounts for the remainder.
Primarily renal (60-80% as metabolites) and biliary/fecal (15-25% as unchanged drug and metabolites).
Category C
Category C
Retinoid
Retinoid